Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial

Cancer

Volumn 100, Issue 12, 2004, Pages 2613-2621

  Rosen, Lee S ^a   Gordon, David ^b   Tchekmedyian, N Simon ^c   Yanagihara, Ronald ^d   Hirsh, Vera ^e   Krzakowski, Maciej ^f   Pawlicki, Marek ^g   De Souza, Paul ^h   Zheng, Ming ⁱ   Urbanowitz, Gladys ⁱ   Reitsma, Dirk ⁱ   Seaman, John ⁱ  

^a Cancer Institute Medical Group   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c Pacific Shores Medical Group   (United States)

^d Hazel Hawkins Hospital   (United States)

^e ROYAL VICTORIA HOSPITAL   (Canada)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g Klinika Chemotherapii Ctr Onkologii   (Poland)

^h ST GEORGE HOSPITAL   (Australia)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bisphosphonate; Bone metastases; Lung; Metastasis; Pulmonary carcinoma; Renal; Solid tumors; Thyroid; Zoledronic acid

Indexed keywords

PLACEBO; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE METASTASIS; BONE PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID TUMOR; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DIPHOSPHONATES; DOUBLE-BLIND METHOD; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; PLACEBOS;

EID: 2642521168     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20308     Document Type: Article

References (12)

1. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer. 1997;80(8 Suppl):1529-1537.
2. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(Suppl):1588-1594.
3. Nottebaert M, Exner GU, von Hochstetter AR, Schreiber A. Metastatic bone disease from occult carcinoma: a profile. Int Orthop. 1989;13:119-123.
4. Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 2001;19:379-382.
5. Pittas AG, Adler M, Fazzari M, et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid. 2000;10:261-268.
6. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1-18.
7. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.
8. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
9. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150-3157.
10. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558-567.
11. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10:1100-1120.
12. Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer. 2002;94:2521-2533.